Tan Eng Huat
陈英发
MBBS, MRCP (UK), FAMS
Senior Consultant, Division of Medical Oncology; Adjunct Professor, Duke-NUS Medical School肿瘤内科高级顾问；杜克-新加坡国立大学医学院兼职教授
👥Biography 个人简介
Tan Eng Huat, MBBS, MRCP (UK), FAMS is a Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) and Adjunct Professor at Duke-NUS Medical School. He is one of Southeast Asia's leading clinician-scientists in nasopharyngeal carcinoma (NPC), a cancer of major public health significance in the region. Dr. Tan has contributed extensively to defining the role of platinum-based chemotherapy regimens in locoregionally advanced and metastatic NPC, and has led landmark Asian cooperative group trials including studies of gemcitabine-cisplatin chemotherapy and concurrent chemoradiotherapy optimization in this EBV-related malignancy. He has played a critical role in establishing the efficacy of PD-1 checkpoint inhibitors (camrelizumab, nivolumab) in recurrent/metastatic NPC through international and regional phase III trials. Dr. Tan serves on multiple international HNSCC guideline committees and has mentored a generation of Asian NPC investigators.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Gemcitabine-Cisplatin in Recurrent/Metastatic NPC
Led or co-led the phase III trial demonstrating superiority of gemcitabine plus cisplatin over fluorouracil plus cisplatin as first-line chemotherapy for metastatic or recurrent NPC, establishing a new Asian and international standard of care that remained dominant for over a decade.
PD-1 Blockade in Recurrent/Metastatic NPC
Contributed to phase II and III trials evaluating camrelizumab (SHR-1210), sintilimab, and nivolumab in R/M NPC, providing evidence for immunotherapy benefit in EBV-positive NPC due to high PD-L1 expression and immune-rich tumor microenvironment.
Concurrent Chemoradiotherapy Optimization in NPC
Participated in SEER and Asian cooperative group trials refining cisplatin dosing schedules, induction chemotherapy sequences, and radiotherapy fractionation for locoregionally advanced NPC, improving locoregional control and long-term survival.
Asian Cooperative Oncology Group (ACOG) Leadership
Served in leadership roles in Asian cooperative oncology networks, designing and conducting NPC clinical trials specifically relevant to Asian patient populations and contributing to harmonization of treatment guidelines across Southeast Asia.
Representative Works 代表性著作
Randomized trial of gemcitabine-cisplatin versus fluorouracil-cisplatin in recurrent or metastatic nasopharyngeal carcinoma
Journal of Clinical Oncology (2005)
Phase III randomized trial demonstrating superiority of gemcitabine-cisplatin in overall response rate and time to progression vs. fluorouracil-cisplatin in recurrent/metastatic NPC.
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
The Lancet Oncology (2021)
Phase III CAPTAIN-1st trial showing camrelizumab plus chemotherapy significantly improved PFS vs. chemotherapy alone as first-line treatment for R/M NPC.
Concurrent cetuximab versus cisplatin with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a phase II study
Annals of Oncology (2015)
Phase II randomized study comparing EGFR inhibitor cetuximab with standard cisplatin concurrent with radiotherapy in locally advanced NPC, informing selection of optimal concurrent agent.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 陈英发 的研究动态
Follow Tan Eng Huat's research updates
留下邮箱，当我们发布与 Tan Eng Huat（National Cancer Centre Singapore）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment